Latest Insider Positions


GROENHUYSEN WILHELMUS CM is listed as an insider in the following companies: NVCR / NovoCure Limited Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Holdings

Security Title Post Shares
NVCR / NovoCure Chief Financial Officer 37,124

Latest Transactions

Latest
Tran Date
Security Code Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2018-08-27 NVCR / NovoCure S -9,973 37,124 -21.18 40.0284 -399,203 1,486,014 -26.86
2018-08-24 NVCR / NovoCure S -100 47,097 -0.21 40.05 -4,005 1,886,235 -0.21
2018-08-24 NVCR / NovoCure S -200 47,197 -0.42 40.025 -8,005 1,889,060 -0.42
2018-08-24 NVCR / NovoCure S -25,274 47,397 -34.78 40.00 -1,010,960 1,895,880 -53.32
2018-08-22 NVCR / NovoCure S -31,179 72,671 -30.02 37.6729 -1,174,603 2,737,727 -42.90
2018-08-14 NVCR / NovoCure S -2,300 103,850 -2.17 37.50 -86,250 3,894,375 -2.21
2018-08-14 NVCR / NovoCure S -100 106,150 -0.09 37.60 -3,760 3,991,240 -0.09
2018-08-14 NVCR / NovoCure S -300 106,250 -0.28 37.65 -11,295 4,000,312 -0.28
2018-08-14 NVCR / NovoCure S -200 106,550 -0.19 37.55 -7,510 4,000,952 -0.19
2018-08-14 NVCR / NovoCure S -500 106,750 -0.47 37.75 -18,875 4,029,812 -0.47
2018-08-14 NVCR / NovoCure S -200 107,250 -0.19 37.70 -7,540 4,043,325 -0.19
2018-08-14 NVCR / NovoCure S -68 107,450 -0.06 37.80 -2,570 4,061,610 -0.06
2018-08-14 NVCR / NovoCure S -200 107,518 -0.19 38.00 -7,600 4,085,684 -0.19
2018-08-14 NVCR / NovoCure S -400 107,718 -0.37 37.90 -15,160 4,082,512 -0.37
2018-08-14 NVCR / NovoCure S -100 108,118 -0.09 37.85 -3,785 4,092,266 -0.09
2018-08-02 NVCR / NovoCure S -1,790 108,218 -1.63 35.05 -62,740 3,793,041 -1.65
2018-08-02 NVCR / NovoCure S -5,336 110,008 -4.63 35.00 -186,760 3,850,280 -4.85
2018-08-01 NVCR / NovoCure S -100 115,344 -0.09 35.05 -3,505 4,042,807 -0.09
2018-08-01 NVCR / NovoCure S -200 115,444 -0.17 35.025 -7,005 4,043,426 -0.17
2018-08-01 NVCR / NovoCure S -941 115,644 -0.81 35.00 -32,935 4,047,540 -0.81
2018-07-27 NVCR / NovoCure S -1,100 116,585 -0.93 37.05 -40,755 4,319,474 -0.94
2018-07-27 NVCR / NovoCure S -6,095 117,685 -4.92 36.60 -223,077 4,307,271 -5.18
2018-07-27 NVCR / NovoCure S -34,385 123,780 -21.74 35.20 -1,210,352 4,357,056 -27.78
2018-07-27 NVCR / NovoCure S -17,437 158,165 -9.93 34.44 -600,530 5,447,203 -11.02
2018-07-27 NVCR / NovoCure S -3,710 175,602 -2.07 33.86 -125,621 5,945,884 -2.11
2018-07-06 NVCR / NovoCure A 1,191 179,312 0.67 17.255 20,551
2018-05-14 NVCR / NovoCure S -280 178,121 -0.16 30.25 -8,470 5,388,160 -0.16
2018-05-14 NVCR / NovoCure S -200 178,401 -0.11 30.225 -6,045 5,392,170 -0.11
2018-05-14 NVCR / NovoCure S -200 178,601 -0.11 30.20 -6,040 5,393,750 -0.11
2018-05-14 NVCR / NovoCure S -1,772 178,801 -0.98 30.15 -53,426 5,390,850 -0.99
2018-05-14 NVCR / NovoCure S -4,927 180,573 -2.66 30.10 -148,303 5,435,247 -2.73
2018-05-14 NVCR / NovoCure S -100 185,500 -0.05 30.075 -3,008 5,578,912 -0.05
2018-05-14 NVCR / NovoCure S -3,590 185,600 -1.90 30.05 -107,880 5,577,280 -1.93
2018-05-14 NVCR / NovoCure S -10,008 189,190 -5.02 30.00 -300,240 5,675,700 -5.29
2018-05-11 NVCR / NovoCure S -2,700 199,198 -1.34 30.025 -81,068 5,980,920 -1.36
2018-05-11 NVCR / NovoCure S -6,693 201,898 -3.21 30.00 -200,790 6,056,940 -3.32
2018-05-01 NVCR / NovoCure S -30,470 208,591 -12.75 27.58 -840,363 5,752,940 -14.61
2018-02-23 NVCR / NovoCure S -13,351 239,061 -5.29 19.828 -264,724 4,740,102 -5.58
2018-02-22 NVCR / NovoCure M 43,334 252,412 20.73 21.55 933,848
2018-01-09 NVCR / NovoCure S -31,132 209,078 -12.96 21.0194 -654,376 4,394,694 -14.89
2018-01-08 NVCR / NovoCure A 310 240,210 0.13 15.045 4,664
2018-01-04 NVCR / NovoCure S -26,264 239,900 -9.87 21.0293 -552,314 5,044,929 -10.95
2018-01-03 NVCR / NovoCure S -2,404 266,164 -0.90 21.00 -50,484 5,589,444 -0.90
2018-01-03 NVCR / NovoCure S -200 268,568 -0.07 21.025 -4,205 5,646,642 -0.07
2017-07-05 NVCR / NovoCure A 2,484 268,768 0.93 6.673 16,576
2017-01-06 NVCR / NovoCure A 3,156 266,284 1.20 6.673 21,060
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Peers of GROENHUYSEN WILHELMUS CM include the following: Ambrogi Michael J., Avista Capital Partners (Offshore) II, L.P., Avista Capital Partners (Offshore) II-A, LP, Avista Capital Partners II GP, LLC, Avista Capital Partners II, L.P., Bierly Rick, Bradshaw Paul, Burkoth William T., DOYLE WILLIAM F, Danziger Asaf, Entrepreneurs Fund General Partner Ltd, Entrepreneurs Fund LP, FUTRELL STEVE, GRANOFF MICHAEL D, Gibbs Thomas Edward, Goldan Keith A., HELTON SANDRA L, HILLEMAN JERYL L, Hung David, JANIS FRANCES, Kirson Eilon D., LAVIGNE LOUIS J JR, LEUNG GABRIEL, Langloss Timothy J., Longsworth Todd Christopher, MYLOD ROBERT J JR, Madden Martin J., Mahmoud Ramy A, Marino Michael F III, McCoy Sherilyn S, Melnyk Peter M., Miller Peter K, O'Neil Robert P, PHILLIPS CHARLES G III, Palti Yoram, Perlhagen Gert L., Pickering Larry G, Pomona Associates VII, L.P., Pomona Capital VII Fund Investors, L.P., Pomona Capital VII, L.P., Pomona G.P. Holdings LLC, Pomona Secondary Associates VII LLC, Scodari Joseph C, Shah Pritesh, TKWD Ventures LLC, Tamaroff Joshua Alexander, VERNON W ANTHONY, Venkataraman Sriram, Volati Ltd, WFD Ventures Fund II, L.P., WFD Ventures LLC, Wyss Hansjoerg, . Peers are determined by cross-linking the filings of GROENHUYSEN WILHELMUS CM with insider filings of others at the same companies.

Related News Stories

3 Medical Devices Stocks to Buy

2018-10-02 investorplace
When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. (0-1)

Under Armour Has Bottomed - Cramer's Lightning Round (10/1/18)

2018-10-02 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, October 1. (31-0)

Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

2018-09-26 seekingalpha
Verastem had its ups and downs in 2018, but they've finally gotten their first drug approval in non-Hodgkin lymphoma. (45-2)

Investing In The 'Softer Side' Of Biotech, Without Getting Emotional

2018-09-18 seekingalpha
Biotechs have been a bit bumpy lately due to lack of anticipated M&A action, with record outflows from some of the sector's largest ETFs, including XBI and IBB. (61-0)

Week In Review: $1.4 Billion In China Life Science Deals And Financings

2018-09-17 seekingalpha
Vivo Capital, a US-China healthcare investment firm, closed a new private equity fund at an oversubscribed $635 million. The Vivo Opportunity Fund will invest in the US and China small to mid-cap public life sciences companies with novel products in development. Vivo raised $750 million for its previous PE fund in 2015, and it closed a $100 million venture capital fund in 2016. The firm, which has offices in Palo Alto, Beijing, Shanghai and Taipei, now has $2.